In the livers of humans and many other mammalian species, β 2 -adrenergic receptors (β 2 -ARs) play an important role in the modulation of glucose production by glycogenolysis and gluconeogenesis. In male mice and rats however, the expression and physiological role of hepatic β 2 -ARs are rapidly lost with development under normal physiological conditions. We previously described a line of transgenic mice, F28, which carry the human β 2 -AR gene under the control of its own promoter. In these mice, hepatic β 2 -AR levels are shown to rapidly increase after birth, and, as in humans, be maintained at an elevated level in adulthood. F28 mice display strongly enhanced adenylyl cyclase responses to β-AR agonists in their livers and, compared to normal mice, have increased basal hepatic adenylyl cyclase activity. In this report we demonstrate that under normal physiological conditions this increased β 2 -AR activity affects the expression of the gluconeogenic and glycolytic key enzymes phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase) and Lpyruvate kinase (L-PK), and considerably decreases hepatic glycogen levels. Furthermore, we show that the effects of β-adrenergic ligands on liver glycogen observed in humans are reproduced in these mice: liver glycogen levels are strongly decreased by the β 2 -AR agonist clenbuterol and increased by the β-AR antagonist propranolol. These transgenic mice open new perspectives for studying in vivo the hepatic β 2 -AR system physiopathology, and for testing the effects of β-AR ligands on liver metabolism.
INTRODUCTION

MATERIALS AND METHODS
Animals and tissues.
Unless indicated otherwise, 8-week-old F28 male mice (2) have been used for this study. As hepatic β-AR expression is the same in C57BL/6 males and in nontransgenic littermate males, C57BL/6 males (Iffa Credo, Lyon, France) were used as controls (Co) for comparison. The body mass (body mass index) of the F28 and the Co mice was 15.5±0.6 (0.20±0.01) and 25±1 (0.24±0.01), respectively (n=15). All mice were housed in colony cages with a 12-h light/dark cycle. Except for the fasting experiments, mice had free access to water and food (granulated diet; in terms of energy: 65% carbohydrate, 11% fat, 24% protein, UAR). Mice were killed by means of an intraperitoneal pentobarbital injection (70 mg/kg body weight) followed by a cervical dislocation. The livers were dissected out within 30 s, immediately frozen and powdered in liquid nitrogen, and kept at -80 °C until further analysis. In some experiments, hindlimb muscles were also rapidly removed, frozen, powdered in liquid nitrogen and kept at -80°C until glycogen assays were performed.
For the fasting and refeeding studies, mice from each species (F28, C57BL/6) were divided into two groups. The first group (fasted group) was fasted for 24 h, and the second one (refed group) was fasted for 24 h and then refed for 18 h with a high carbohydrate diet (in terms of energy: 72.2% carbohydrate, 1% fat, 26.8% protein). The animals were killed and the livers sampled as described above.
All animal procedures were conducted in accordance with French government regulations (Services Vétérinaires de la Santé et de la Production Animale, Ministère de l'Agriculture). Plasma membrane preparation. Plasma membranes were prepared as described previously (2) . Briefly, tissues from 1-, 7-, 14-, 21-, 30-, 60-, 90-, 180-day-old mice were homogenized in 50mM Tris / 5mM EDTA / 250mM sucrose supplemented with a protease inhibitor cocktail (Roche, Mannheim, Germany). The particulate fraction was centrifuged at 1,500xg for 10 min and the pellet dispersed in 75mM Tris / 5mM EDTA / 12.5mM MgCl 2 supplemented with the protease inhibitor cocktail and 10% glycerol. All procedures were performed at 4°C. The membrane preparations were stored at -80°C until use. For binding studies the membranes were washed twice with PBS / 10% glycerol and resuspended in PBS immediately before the assay; for adenylyl cyclase studies they were washed once with and resuspended in 25mM Tris / 1mM EDTA. Protein concentrations were determined with a BCA protein assay kit (Pierce, Rockford, IL, USA) using BSA as standard. Binding experiments. We proceeded as described previously (2) . Saturation binding experiments were performed on 10-20µg plasma membrane proteins with the β-AR 125 I] CYP plus 50nM of the β 2 -adrenoceptor selective antagonist ICI 118,551 or 500nM of the β 1 -adrenoceptor selective antagonist CGP 20,712A (both ligands from Zeneca Pharmaceuticals, Macclesfield, Cheshire, England). Non-specific radioligand binding was evaluated by incubating in the presence of 1µM (-)-propranolol (Sigma Chemical Co, St Louis, MO, USA). Adenylyl cyclase assay. The assays for evaluation of the responsiveness of adenylyl cyclase to isoproterenol, Gpp[NH]p (5'-guanylylimidodiphosphate) and forskolin (all provided by Sigma Chemical Co, St Louis, MO, USA), were performed as described elsewhere (2) . To determine the maximal agonist-induced adenylyl cyclase response, incubations were done in presence of 10µM (-) isoproterenol. For determination of the maximal G-protein-induced and the maximal non receptor-mediated stimulation of adenylyl cyclase, incubations were done in presence of 100µM Gpp[NH]p and 1mM forskolin, respectively.
Administration of antagonists and agonists.
Extreme care was taken to avoid stressful experimental conditions for the animals since these can alter the catecholamine release, and thus possibly confound the β 2 -adrenergic agonist or antagonist actions. The agonist clenbuterol (Sigma Chemical, St Louis, MO) and the antagonist propranolol (Avlocardyl  , Zeneca-Pharma, France) were therefore administered via ingested beverage instead of injection (drug concentration: 2.6mg and 7mg per liter water, respectively). The treatments were initiated at 5 p.m. and lasted until the next day for clenbuterol and two days later for propranolol. Food consumption. Commercial rodent pellets were powdered and given to the animals in feeding trays for powdered food (UAR, Epinay sur Orge, France) allowing the quantification of the amount of ingested food. Two individual series of daily measurements were made for one week each, on three individual animals from each group (F28, C57BL/6). The quantity of daily ingested food was expressed as % of the animal's body mass. Blood glucose determination. A Glucomatic  Esprit apparatus (Bayer) was used for determination of the blood glucose concentration. Glucose content was measured as indicated by the manufacturer in a drop of blood taken from the tail vein. Liver and muscle glycogen determination. Glycogen content was determined as described elsewhere (18) . Briefly, 200mg of powdered tissue stored at -80°C were homogenized with an ultra-turax in 1ml HClO 4 at 4°C for extraction and deproteinization. 200µl of the homogenate were first treated for 2 hrs at 40°C with α-amyloglucosidase in acid buffer for glycogen hydrolysis, and then centrifuged at 14,000rpm for 10 min after acidification with HClO 4 . The remaining 800µl of the homogenate were immediately neutralized with solid KHCO 3 and centrifuged at 14,000rpm during 10 min in order to determine the tissue glucose amount that did not result from glycogen hydrolysis. The glucose content was assayed in both supernatants using an UV method for the determination of D-glucose (Boehringer Mannheim kit) according to the manufacturer's instructions. Tissue glycogen was expressed as mmol of glucose resulting from glycogen hydrolysis/gr of tissue. Histological revelation of glycogen. 10µm thin cryostat sections were made from livers of untreated, clenbuterol-treated, and propranolol-treated 8-week-old F28 and Co mice killed either at 8 am or at 5 pm as indicated. Glycogen was visualized with periodic acid-Schiff staining (9) . Northern blot analysis. Total RNA was extracted from 200mg liver tissue using the guanidinethiocyanate method (4) . Northern blot analysis was performed as described (24) . 20µg mRNA were run on 1% agarose gels and transferred onto Hybond N + membranes (Amersham). Northern blot analyses were performed using a 569 bp fragment spanning exons 1-4 of the mouse PEPCK cDNA (35), a 1.25 Kb EcoRI-HindIII fragment from the rat G6Pase cDNA (11), a 700 bp PvuII fragment of the rat GK cDNA and a 1.8-Kb pair PstI fragment from the rat cDNA PK G4 as specific probes for the PEPCK, G6Pase, GK and L-PK mRNA respectively (24) . To normalize the signals, blots were hybridized with a 700 bp HindIIIEcoRI fragment, cyclophillin-specific probe, derived from a rat cDNA plasmid (24) . Band intensity was determined by optical density (NIH Image, v1.62). Real-time quantitative PCR. Real-time Quantitative PCR analysis was done as described (6) . Total RNA (500 ng) was reverse-transcribed for 1 h at 42 °C in a 20-µl final volume reaction containing 50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol, 250 mM random hexamers (Promega), 250 ng of oligo (dT) (Promega), 2 mM of each dNTPs, and 100 units of superscript II reverse transcriptase (Invitrogen). Real-time quantitative PCR analysis was performed starting with 6.25 ng of reverse-transcribed total RNA, in a final volume of 10-µl PCR reaction, with 0.5 µM of the earlier described (6) cyclophilin-, L-PK-and GKspecific primers (Invitrogen), 2 mM MgCl 2 , using 1x light cycler DNA Master SYBR Green I mix in a light cycler instrument (Roche Applied Science). Samples were incubated in the light cycler apparatus for an initial denaturation at 95 °C for 10 min, followed by 40 cycles. Each cycle consisted of 95 °C for 15 s, 58 °C for 7 s, and 72 °C for 15 s. SYBR Green I fluorescence emission was determined after each cycle. The relative amounts of the different mRNAs were quantified by using the second derivative maximum method of the light-cycler software. Cyclophilin was used as an invariant control, and the relative quantification for a given gene was corrected to the cyclophilin mRNA values. Amplification of specific transcripts was confirmed by melting curves profiles generated at the end of each run. PCR specificity and product length were further checked by agarose gel electrophoresis and ethidium bromide staining. Statistical analysis. All results are presented as means ± S.E.M. The significance of differences between means of two groups was assessed by using the Student's t-test for unpaired variables, and between more than two groups using ANOVA, which was followed, when significant, by post hoc Bonferoni corrected t-tests. Significance of difference between F28 and control mice was indicated in the figures by: "ns" for p ≥ 0.05; " * " for p < 0.05; and " ** " for p < 0.02. Differences were considered statistically significant at p < 0.05.
RESULTS
The hepatic β 2 -AR system expression in F28 and control mice. In Co animals, the hepatic β-AR density was highest at birth and decreased with development: dropping by nearly 50% in the first week after birth, and then declining progressively to ≈15% of the initial value at 3 months of age. The hepatic β-AR expression in F28 mice was similar to Co mice in the immediate postweaning period but increased thereafter and, at 14 days after birth, reached a maximal level that was maintained for at least 6 months. Competition binding experiments with the β 1 -and the β 2 -AR selective antagonists, CGP 20,712A and ICI 118,551 respectively, indicated that β 1 -AR numbers remained at a constant low level for all chosen ages in both Co and F28 mice (14±3 and 23±3 fmol/mg, respectively). Therefore, the developmental patterns of receptor expression in Fig. 1A mainly reflect β 2 -AR density changes.
We further investigated the relationship between β-AR expression and G protein/adenylyl cyclase signal transduction system. We measured the adenylyl cyclase response to forskolin (1mM) which stimulates the enzyme directly (Fig. 1B) , to Gpp[NH]p (100µM) which activates all G-proteins (Fig. 1C) , and to the β-AR agonist isoproterenol (10µM) (Fig. 1D) . The developmental patterns of the forskolin-induced adenylyl cyclase response in F28 and Co mice were similar (Fig. 1B) . However the ontogenetic patterns of total G-protein and β-AR agonist-induced responses were different (Figs. 1C and 1D respectively). Gpp[NH]p-induced responses were slightly, but significantly, higher for F28 than for Co mice (p<0.05 at PN1, 14, 30, 60 and 90). A large difference was observed in the isoproterenol-induced response. In F28 mice the response showed a marked increase over controls, reaching a maximum level within two weeks after birth, while in Co mice, the response decreased to levels close to basal activity (4.2±0.8 pmol/min/mg protein). Both types of mice maintained their respective characteristics across the 6 months age range studied. Liver glycogen and glycemia in F28 and control mice under normal physiological conditions. The basal adenylyl cyclase activity in the F28's liver is about twofold higher than in Co mice (1) . We investigated whether this affects the glycogen accumulation/degradation and/or blood glucose concentration under normal physiological conditions. Normally, hepatic glycogen stores are degraded during the postabsorptive phase and refilled during the absorptive phase. Analyses were therefore performed at the beginning (8 am) and the end (5 pm) of the postabsorptive phase. We visualized hepatic glycogen stores histochemically in liver cryostat slices (Fig. 3) and assayed the overall liver glycogen content in tissue homogenates ( Fig. 2A) .
For untreated F28 mice (F28 NT ), the overall tissue glycogen yield at 8 am was approximately half of that in Co NT ( Fig. 2A 1 ). Yet, glycogen was demonstrable in most hepatocytes of both, untreated Co mice (Co NT ) and untreated F28 mice (F28 NT ) (Figs. 3A and B respectively). At 5 p.m., the overall glycogen yield decreased by 60-70% in both Co NT and F28 NT mice ( Fig. 2A 1 ) . Glycogen remained detectable in most Co NT mouse hepatocytes (Fig.  3G ) but in F28
NT mouse livers, glycogen-depleted areas were observed (Fig. 3H ). The lower glycogen levels in F28
NT mouse livers did not appear to be due to a deficit in food absorption: consumed food mass versus body mass was similar for both groups of animals (Fig. 2C) . Administration of the β-AR antagonist propranolol (Co Prop , F28 Prop )
however, considerably reduced the difference in glycogen levels ( Fig. 2A 1 ) and glycogen distribution between the two animals at 8 am and 5 pm (Figs. 3E-F and 3K-L respectively) supporting the idea that the decreased glycogen levels in F28 NT may be due to the overexpression of hepatic β 2 -ARs.
The hepatic β 2 -adrenergic system plays an important role in the maintenance of blood glucose homeostasis via glycogenolysis and gluconeogenesis. Since glycogen storage is modified in F28
NT versus Co NT mice, we checked whether blood glucose levels were changed. Levels of plasma glucose in F28 NT mice were slightly but significantly lower than in Co NT mice at 8 am and 5 pm, and this decrease in F28 mice was inhibited by propranolol (Fig. 2B) . The muscles of F28 mice have higher levels of β 2 -ARs than those of Co mice (2). The differences in glycogen content between the animals could be a result of lower blood glucose caused by increased glucose uptake in the muscle. To examine the validity of this hypothesis we assayed glycogen in hindlimb muscles of F28
NT and Co NT mice ( Fig. 2A 2 ) . Muscle glycogen levels in F28
NT animals did not differ statistically from those in Co NT mice. Moreover, glycogen levels in the muscles did not change significantly upon treatment of the animals with propranolol.
Effect of the β 2 -adrenergic agonist clenbuterol on liver glycogen and glycemia in F28 and control mice. In vitro experiments on membrane preparations (Fig. 1D) Fig. 2A 1 ) . Glycogen levels measured at 8 am in Co Clenb resembled those measured in F28 NT mice ( Fig.  2A 1 ) . Also at 5 pm, liver glycogen in Co clenb and F28 Clenb differed considerably: depletion of glycogen stores in the liver was only partial for Co Clenb (Fig. 3I ) but nearly total for F28 Clenb (Fig. 3J ). Mice consumed less food when treated with clenbuterol, yet, differences in the clenbuterol effects in F28 clenb vs Co clenb mice were most likely not due to differences in food consumption since amounts of ingested food vs body mass remained similar for both animal groups (Fig. 2C) .
Clenbuterol had no effect on blood glucose levels. At 8 am no statistical difference was observed in the level of blood glucose concentrations in F28
Clenb and Co Clenb compared to F28
NT and Co NT respectively (Fig. 2B) . Expression of GK, L-PK, G6Pase and PEPCK. After demonstrating that hepatic β 2 -AR overexpression considerably perturbs the hepatic glycogen storage/degradation, we examined whether this affects the expression of the GK, L-PK, G6Pase and PEPCK gene (Figs. 4A-D) . Levels of L-PK, G6Pase and PEPCK mRNA in Co NT mice were the lowest at the beginning of the postprandrial period (8 am), and increased significantly (p<0.02) during this period (Figs.  4B-D) . Levels of GK mRNA did not significantly change during the postprandrial period (p>0.05) (Fig. 4A) . At 8 am, there was no statistical difference between GK mRNA levels in Co NT and F28 NT mice (Fig. 4A) while L-PK, and especially G6Pase and PEPCK mRNA levels, were higher in F28
NT than in Co NT ( Fig. 4C and D) . At 5 pm however, L-PK and G6Pase mRNA levels (Figs. 4B and C) were lower in F28
NT than in Co NT while GK and PEPCK mRNA levels (Figs. 4A and D) were similar in both animals.
The modulation of L-PK and GK gene transcription is an immediate index of the modulation of the glycolytic rate. The expression of both genes can be acutely regulated by the 24 hr fasting and refeeding with high carbohydrate (HCHO) diet (6) . To further examine extent to which the hepatic β 2 -AR overexpression affects the expression of both enzymes, we monitored the L-PK and GK gene expression and the blood glucose levels in Co and F28 mice in both fasting and refeeding conditions. In both groups of mice, GK and L-PK mRNA levels were low after a 24 hr fast and markedly increased upon refeeding with a HCHO diet (Figs. 5A and B) . However, GK mRNA levels were significantly higher and L-PK mRNA levels significantly lower in refed F28 mice compared to control. Blood glucose levels decreased to similar levels in F28 and Co mice upon fasting (Fig. 5C ). Upon refeeding, blood glucose levels increased over Co NT and F28 NT (Fig. 2B ) levels but were significantly lower in F28 than in Co mice (Fig. 5C ).
DISCUSSION
We previously described a transgenic mouse line F28 that carries the human β 2 -AR gene under the control of its natural promoter (2) . Unlike wild type Co mice, hepatic β 2 -AR levels in these mice increase after birth. At young adulthood, these mice have 10 fold more functional β 2 -ARs in their livers than wild type controls. With this high β 2 -AR expression, F28 mice have β 2 -AR levels comparable to those reported in the human liver (8, 29) . As in humans, they maintain this elevated level of β 2 -AR expression through adulthood and display strongly enhanced hepatic adenylyl cyclase responses to β-AR agonists (Fig. 1) . Their basal hepatic adenylyl cyclase activity is also higher than in Co mice, probably due to an increased number of constitutively active β 2 -ARs (1).
A substantial body of data (reviewed in 20) indicates that the liver plays a central role in the control of food intake, metabolism, and body weight. Under normal physiological conditions in human and many animal species, the hepatic β 2 -AR/adenylyl cyclase system is a major modulator of many metabolic processes (20, 23, 26, 28, 33) . In an earlier study we demonstrated the potential of the F28 mouse model for studying the physiopathological importance of the hepatic β 2 -AR system and found that F28 mice were naturally protected against lethal and fulminant Fas-dependent liver apoptosis(1), probably due to increased basal hepatic β 2 -AR activity. In the present study, we focused on the metabolic changes induced by increased β 2 -AR expression in the F28 mouse liver and examined the effects of β-adrenergic ligands on the liver's metabolism.
In the human liver, glycogenolysis occurs primarily via a β 2 -AR/cAMP-dependent mechanism (26, 28) while in the adult rat liver, hepatic glycogenolysis is mediated by a cAMP-independent mechanism involving α 1 -ARs (16, 28) . Our study demonstrates that in F28 mice, the hepatic β 2 -AR system is also a major modulator of liver glycogen accumulation and/or degradation. Under normal physiological conditions, we found that the F28 mouse liver contains about half glycogen of the normal mouse liver ( Figs. 2A and 3 ). These deficiencies did not appear to be due to a different nutritional behavior since food consumption was similar for both mouse lines (Fig. 2C) . Differences appear to be neither due to the higher β 2 -AR levels, nor to an increased glucose uptake in the muscles of F28 mice (2); indeed, glycogen levels in the muscles of control mice did not differ significantly from those in F28 mice and were not altered upon treatment of the animals with propranolol. It can however, reasonably be hypothesized that decreased glycogen accumulation and/or increased glycogen degradation is due to the approximately two-fold increased hepatic basal β 2 -AR activity in F28's liver (1). This is supported by the fact that differences in liver glycogen levels were almost totally abolished upon pretreatment with the β-AR antagonist propranolol. Perhaps one of the most interesting features of the F28's hepatic β 2 -AR system is that the effect of the β 2 -AR agonist clenbuterol on liver glycogen is strongly increased: compared to untreated animals, liver glycogen is moderately decreased in Co Clenb mice but severly depleted in F28 clenb mice (Figs. 2 and 3) . Regulation of cAMP levels by glucagon, insulin, and catecholamines accounts in large part for minute-to-minute hormonal control of pathway flux in fed animals and during the transition from fed to starved. Cyclic AMP plays a key role in the regulation of gene transcription of gluconeogenic and lipolytic enzymes: it enhances the transcription of genes encoding hepatic enzymes, such as PEPCK, which in turn induces glucose production (7, 30) , and regulates negatively the transcription of L-PK gene, a key enzyme of glycolysis (5). In the liver, GK activity is regulated at the level of gene transcription in response to fasting and refeeding (15, 22) , and its transcription is negatively regulated by glucagon through increases in cAMP concentration (13, 14, 31, 32) .
We demonstrate here that the increased hepatic β 2 -AR expression in the F28 mice affects the metabolic pathways that are involved in glycolysis and gluconeogenesis (Fig. 4) . Indeed, already under normal physiological conditions the expression of the L-PK, G6Pase and PEPCK genes in F28 mice differs from that observed in control mice. Hence, mRNA levels of L-PK, G6Pase and PEPCK in the liver are low at 8 am and increase considerably during the postabsorptive phase in Co mice, but are already maximal at 8 am in F28 mice. Under these physiological conditions, however, GK mRNA levels in the livers of the F28 mice did not significantly differ from those measured in Co mice.
Refeeding with a high carbohydrate diet after a 24 hr fast induced, as expected (6), the expression of GK and L-PK genes in the liver of both control and F28 mice. Surprisingly however, GK mRNA levels in refeeding conditions were higher in F28 mice than in Co mice while L-PK mRNA levels were lower (Fig. 5) . Considering that the basal adenylyl cyclase activity in the F28's liver is increased when compared to the Co mice (1, 2) , and that the GK gene transcription is negatively regulated by cAMP (14, 31) , the increased GK expression in the F28 mice is intriguing. It suggests that the glycolytic flux is increased in the F28's liver compared to control, although hepatic glycogen stores are lower in F28 than in Co mice. Nevertheless, the increased GK expression might explain the low blood glucose concentration observed in the F28 mice in normal physiological conditions and in fasting/refeeding conditions as well (Figs. 2 and 5 ). It has been reported that hepatic β 2 -ARs activation elicits hyperglycemic responses (25) , and that decreased hepatic β 2 -AR activity can lead to the development of hypoglycemia (35) . It has also been shown that even small increases in the expression of hepatic GK lead to a decreased blood glucose level (24) . In this context it is worth noting that the blood glucose levels measured in the F28 mice closely resemble those observed in transgenic mice that overexpress GK (24) .
The decreased L-PK (Fig. 5) gene transcription in the liver of the F28 mice compared to controls might be caused by the increased hepatic basal adenylyl cyclase activity. Cyclic AMP is known to negatively regulate the L-PK gene transcription (5, 14) . The decreased L-PK gene transcription consistent with a decreased glycolytic flux and fits the strongly increased expression of the gluconeogenetic enzyme, PEPCK (Fig. 4) . These regulations should lead to increased blood glucose levels, which were not observed in the F28 mice.
These apparently contradictory regulations might, however, reflect a series of compensatory adaptations that might take place in the F28 mice to maintain euglycemia. The interrelationship between the different mechanisms that are involved in vivo in glycogenolysis, gluconeogenesis, and blood glucose homeostasis is extremely complex and the precise modulatory role of the F28's hepatic β 2 -AR system remains to be clarified.
In conclusion, F28 mice maintain, as do humans, an elevated level of β 2 -AR expression in their livers in adulthood and display strongly enhanced adenylyl cyclase responses to β-AR agonists. This study showed that under normal physiological conditions, the increased β 2 -AR activity alters the expression of the gluconeogenic and glycolytic key enzymes phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase) and Lpyruvate kinase (L-PK) and decreases hepatic glycogen levels and blood glucose levels. Moreover, the effects of β-adrenergic ligands on liver glycogen in humans were reproduced in these mice: liver glycogen levels were strongly decreased by the β 2 -AR agonist clenbuterol and increased by the β-AR antagonist propranolol. Due to these physiological characteristics, these transgenic mice offer new possibilities for studying in vivo the hepatic β 2 -AR system physiopathology, and for testing the effects of β-AR ligands on liver metabolism. 
